Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® ...
Pharmaceutical Technology on MSN7d
Ionis and Sobi agree on olezarsen commercialisation
Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.
Morningstar9d
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement ...
Arrowhead Pharmaceuticals Is Finally Arriving
Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...
Investing9d
Ionis licenses olezarsen to Sobi for global reach
The agreement follows the U.S. Food and Drug Administration’s approval of olezarsen, branded as TRYNGOLZA™, in December 2024 as the sole treatment for FCS in the U.S. With a robust current ...
Ionis Pharmaceuticals enters exclusive olezarsen license agreement with Sobi
Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...
Seeking Alpha9d
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis Pharmaceuticals (NASDAQ:IONS) has entered into a license agreement under which Sobi receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen as a ...
Investing9d
Ionis licenses olezarsen to Sobi for global reach
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a $5.1 billion market cap biotechnology company currently trading near its 52-week low, has announced a licensing agreement granting Sobi® exclusive rights ...